04/13/2020
Covid-19 will spur a renaissance in U.S. drug manufacturing.
This hydroxychloroquine shortage is one of several breakdowns related to overseas manufacture of our API's and drugs. The pharma industry has resisted adopting new technologies such as continuous manufacturing given the more proven regulatory pathway of batch manufacturing and the low cost sourcing options overseas. Leave it to a crisis for the government and industry to recognize the imperatives of domestic manufacture. Continuous manufacturing, enabled by technologies such as BrightSpec MRR which can monitor processes in real-time, will enable domestic drug manufacture at lower cost, faster scale-up of production, and a higher quality and hence safer product. I'm looking forward to help make this a reality.
https://lnkd.in/eYhDxDw hashtag hashtag hashtag hashtag hashtag hashtag
In a rush to contribute an antimalarial med to the COVID-19 fight, drugmakers have promised millions of doses for clinical trials and hospitals. But one company, Amneal Pharmaceuticals, likely won't hit its pledge after the government of Finland effectively turned off the tap for necessary ingredien...
FIERCEPHARMA.COM
Amneal faces hydroxychloroquine API shortage after Finland tightens production: report
In a rush to contribute an antimalarial med to the COVID-19 fight, drugmakers have promised millions of doses for clinical trials and hospitals. But one company, Amneal Pharmaceuticals, likely won't hit its pledge after the government of Finland effectively turned off the tap for necessary ingredien...
In a rush to contribute an antimalarial med to the COVID-19 fight, drugmakers have promised millions of doses for clinical trials and hospitals. But one company, Amneal Pharmaceuticals, likely won't hit its pledge after the government of Finland effectively turned off the tap for necessary ingredien...